Total Payments
$610,516
2024 Payments
$173,442
Companies
75
Transactions
1,250
Medicare Patients
3,783
Medicare Billing
$260,233
Payment Breakdown by Category
Research$569,210 (93.2%)
Food & Beverage$27,280 (4.5%)
Travel$13,911 (2.3%)
Education$115.59 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $569,210 | 46 | 93.2% |
| Food and Beverage | $27,280 | 1,144 | 4.5% |
| Travel and Lodging | $13,911 | 54 | 2.3% |
| Education | $115.59 | 6 | 0.0% |
Payments by Type
Research
$569,210
46 transactions
General
$41,306
1,204 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $569,817 | 131 | $0 (2024) |
| Valneva Austria GmbH | $7,070 | 3 | $0 (2022) |
| PFIZER INC. | $3,514 | 100 | $0 (2024) |
| GlaxoSmithKline, LLC. | $3,338 | 120 | $0 (2024) |
| ModernaTX, Inc. | $3,275 | 12 | $0 (2024) |
| Novo Nordisk Inc | $2,848 | 122 | $0 (2024) |
| Lilly USA, LLC | $1,992 | 113 | $0 (2024) |
| SANOFI PASTEUR INC. | $1,779 | 14 | $0 (2024) |
| Amgen Inc. | $1,695 | 74 | $0 (2024) |
| Radius Health, Inc. | $1,681 | 16 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $173,442 | 144 | Eli Lilly and Company ($168,006) |
| 2023 | $56,100 | 155 | Eli Lilly and Company ($51,437) |
| 2022 | $11,090 | 161 | Valneva Austria GmbH ($7,070) |
| 2021 | $2,563 | 121 | Novo Nordisk Inc ($417.50) |
| 2020 | $4,498 | 92 | Eli Lilly and Company ($3,078) |
| 2019 | $43,674 | 219 | Eli Lilly and Company ($36,993) |
| 2018 | $275,923 | 179 | Eli Lilly and Company ($272,086) |
| 2017 | $43,226 | 179 | Eli Lilly and Company ($37,044) |
All Payment Transactions
1,250 individual payment records from CMS Open Payments — Page 1 of 50
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $22.50 | General |
| Category: Diabetes | ||||||
| 12/10/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $17.87 | General |
| Category: Inflammation | ||||||
| 12/09/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $25.53 | General |
| Category: Cardio-renal | ||||||
| 11/25/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $28.49 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/21/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $12.72 | General |
| Category: VACCINES | ||||||
| 11/19/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $25.26 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $22.72 | General |
| Category: Endocrinology | ||||||
| 11/13/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $19.72 | General |
| Category: Diabetes Care | ||||||
| 11/07/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $14.48 | General |
| Category: Inflammation | ||||||
| 11/05/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $19.10 | General |
| 10/31/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $21.17 | General |
| Category: Endocrinology | ||||||
| 10/30/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $17.58 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/25/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $13.24 | General |
| Category: Diabetes | ||||||
| 10/24/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $29.19 | General |
| Category: Diabetes | ||||||
| 10/15/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $20.71 | General |
| Category: Diabetes | ||||||
| 10/14/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), AREXVY | Food and Beverage | In-kind items and services | $15.68 | General |
| Category: VACCINES | ||||||
| 10/10/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $19.59 | General |
| Category: Diabetes | ||||||
| 10/08/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $15.11 | General |
| Category: Inflammation | ||||||
| 10/04/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $27.02 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/03/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $16.71 | General |
| Category: Bone Health | ||||||
| 10/01/2024 | Merck Sharp & Dohme LLC | GARDASIL (Biological), CAPVAXIVE, GARDASIL 9 | Food and Beverage | In-kind items and services | $16.87 | General |
| Category: VACCINE | ||||||
| 09/26/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $32.65 | General |
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $32,463.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $12,318.74 | Research |
| Study: A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-1) | ||||||
| 09/24/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $12.09 | General |
| Category: VACCINES | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2 STUDY OF ONCE-WEEKLY LY3298176 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $137,937 | 3 |
| A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-MONTH TRIAL OF LY3298176 VERSUS PLACEBO IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $109,913 | 3 |
| A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | Eli Lilly and Company | $85,893 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $75,365 | 3 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | Eli Lilly and Company | $32,463 | 1 |
| A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN | Eli Lilly and Company | $25,033 | 1 |
| A STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES AND INCREASED CARDIOVASCULAR RISK | Eli Lilly and Company | $16,672 | 3 |
| A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-1) | Eli Lilly and Company | $12,319 | 1 |
| A STUDY OF RETATRUTIDE (LY3437943) ONCE WEEKLY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE KNEE (TRIUMPH-4) | Eli Lilly and Company | $11,952 | 1 |
| A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED PIVOTAL STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A LIVE-ATTEUATED CHIKUNGUNYA VIRUS VACCINE CANDIDATE (VLA1553) IN ADULTS AGED 18 YEARS AND ABOVE | Valneva Austria GmbH | $7,070 | 3 |
| A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above | SANOFI PASTEUR INC. | $1,700 | 10 |
| A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $946.00 | 1 |
| A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, 18-WEEK TRIAL OF INVESTIGATIONAL DULAGLUTIDE DOSES VERSUS PLACEBO IN PATIENTS WITH TYPE 2 DIABETES ON METFORMIN MONOTHERAPY | Eli Lilly and Company | $919.10 | 1 |
| A PHASE 23, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL AGN-241689 IN EPISODIC MIGRAINE PREVENTION. | Allergan Inc. | $656.00 | 3 |
| A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | Eli Lilly and Company | $535.01 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | Eli Lilly and Company | $490.50 | 3 |
| AN EARLY FEASIBILITY STUDY TO EVALUATE THE SAFETY AND FUNCTIONALITY OF AN INDIVIDUAL ACCRUING DATA ALGORITHM WITH LY3209590 IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $472.00 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | Eli Lilly and Company | $285.00 | 1 |
| RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | Eli Lilly and Company | $206.00 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF THREE TIRZEPATIDE DOSES VERSUS PLACEBO IN PATIENTS WITH TYPE 2 DIABETES, INADEQUATELY CONTROLLED WITH DIET AND EXERCISE ALONE | Eli Lilly and Company | $168.00 | 1 |
| A PHASE 2, PARALLEL, COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $142.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 807 | 1,009 | $136,928 | $65,148 |
| 2022 | 18 | 837 | 1,100 | $130,898 | $63,307 |
| 2021 | 17 | 1,005 | 1,314 | $137,537 | $65,364 |
| 2020 | 19 | 1,134 | 1,616 | $158,013 | $66,413 |
Total Patients
3,783
Total Services
5,039
Medicare Billing
$260,233
Procedure Codes
69
All Medicare Procedures & Services
69 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 116 | 276 | $62,100 | $29,061 | 46.8% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 88 | 88 | $20,592 | $11,902 | 57.8% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 111 | 111 | $20,425 | $9,329 | 45.7% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2023 | 21 | 21 | $7,392 | $3,658 | 49.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 33 | 38 | $5,852 | $2,531 | 43.3% |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | Office | 2023 | 101 | 101 | $4,040 | $1,918 | 47.5% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 23 | 23 | $1,725 | $1,651 | 95.7% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 79 | 79 | $2,844 | $1,507 | 53.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 23 | 23 | $1,242 | $755.32 | 60.8% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 17 | 30 | $2,850 | $736.12 | 25.8% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 22 | 25 | $1,875 | $704.25 | 37.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 13 | 13 | $1,222 | $507.99 | 41.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 31 | 52 | $1,295 | $436.80 | 33.7% |
| 96160 | Administration and interpretation of patient-focused health risk assessment | Office | 2023 | 111 | 111 | $2,664 | $226.72 | 8.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 18 | 18 | $810.00 | $223.38 | 27.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 105 | 203 | $45,675 | $20,944 | 45.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 91 | 91 | $21,294 | $12,591 | 59.1% |
| 99497 | Advance care planning, first 30 minutes | Office | 2022 | 96 | 96 | $17,664 | $8,427 | 47.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 58 | 91 | $14,014 | $6,381 | 45.5% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 26 | 70 | $6,650 | $3,390 | 51.0% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 29 | 29 | $2,175 | $1,984 | 91.2% |
| G0442 | Annual alcohol misuse screening, 15 minutes | Office | 2022 | 98 | 98 | $3,920 | $1,923 | 49.1% |
| G0444 | Annual depression screening, 15 minutes | Office | 2022 | 86 | 86 | $3,096 | $1,658 | 53.6% |
| 90732 | Pneumococcal vaccine, 23-valent | Office | 2022 | 11 | 11 | $1,790 | $1,321 | 73.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 25 | 25 | $2,350 | $1,176 | 50.0% |
About Dr. Mark Kutner, MD
Dr. Mark Kutner, MD is a Internal Medicine healthcare provider based in Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1104875277.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Kutner, MD has received a total of $610,516 in payments from pharmaceutical and medical device companies, with $173,442 received in 2024. These payments were reported across 1,250 transactions from 75 companies. The most common payment nature is "" ($569,210).
As a Medicare-enrolled provider, Kutner has provided services to 3,783 Medicare beneficiaries, totaling 5,039 services with total Medicare billing of $260,233. Data is available for 4 years (2020–2023), covering 69 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Miami, FL
- Active Since 05/08/2006
- Last Updated 10/20/2022
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1104875277
Products in Payments
- TRULICITY (Drug) $77,735
- Ozempic (Drug) $1,426
- TRELEGY ELLIPTA (Drug) $1,300
- PREVNAR - 13 (Biological) $1,101
- FARXIGA (Drug) $763.82
- JARDIANCE (Drug) $741.47
- Vascepa (Drug) $674.34
- ANORO (Drug) $557.43
- MOUNJARO (Drug) $553.52
- Kerendia (Drug) $524.82
- UBRELVY (Drug) $519.65
- EMGALITY (Drug) $478.58
- CHANTIX (Drug) $462.21
- Otezla (Drug) $423.71
- Aimovig (Biological) $370.82
- Cologuard Collection Kit (Device) $365.66
- NOCDURNA (Drug) $355.14
- ENTRESTO (Drug) $340.12
- Rybelsus (Drug) $335.45
- EVENITY (Biological) $327.56
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Miami
Jay Skyler, Md, MD
Internal Medicine — Payments: $2.9M
Internal Medicine $2.9M
Dr. Lukasz Kwapisz
Internal Medicine — Payments: $800,664
Internal Medicine $800,664
Dr. Ian Del Conde Pozzi, M.d, M.D
Internal Medicine — Payments: $499,756
Internal Medicine $499,756
Mr. Angel Carrasco, M.d, M.D
Internal Medicine — Payments: $493,362
Internal Medicine $493,362
Dr. Edward Mezerhane, Md, MD
Internal Medicine — Payments: $470,504
Internal Medicine $470,504
Joanna Lopez, Md, MD
Internal Medicine — Payments: $435,514
Internal Medicine $435,514